RECURSION PHARMACEUTICALS, INC. Amortization of Intangible Assets
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Amortization of Intangible Assets of $11.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $11.70M, a 4.88% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $12.70M, a 8.55% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $12.90M, a 72.00% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $13.40M, a 226.83% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2025 was $50.30M, a 167.55% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2024 was $18.80M, a 121.18% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2023 was $8.50M, a 2142.74% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2022 was $379.00K, a 24.67% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.70M 10-Q · filed 2026-08-05 | $24.40M 10-Q · filed 2026-08-05 | $37.30M derived: sum of 3 quarters · filed 2026-08-05 | $50.70M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $12.70M 10-Q · filed 2026-05-06 | $25.60M derived: sum of 2 quarters · filed 2026-05-06 | $39.00M derived: sum of 3 quarters · filed 2026-05-06 | $51.30M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $26.30M derived: sum of 2 quarters · filed 2026-02-25 | $38.60M derived: sum of 3 quarters · filed 2026-08-05 | $50.30M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $13.40M 10-Q · filed 2025-11-05 | $25.70M derived: sum of 2 quarters · filed 2026-08-05 | $37.40M 10-Q · filed 2025-11-05 | $44.90M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $12.30M 10-Q · filed 2026-08-05 | $24.00M 10-Q · filed 2026-08-05 | $31.50M derived: sum of 3 quarters · filed 2026-08-05 | $35.60M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $11.70M 10-Q · filed 2026-05-06 | $19.20M derived: sum of 2 quarters · filed 2026-05-06 | $23.30M derived: sum of 3 quarters · filed 2026-05-06 | $27.20M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.60M derived: sum of 2 quarters · filed 2026-02-25 | $15.50M derived: sum of 3 quarters · filed 2026-02-25 | $18.80M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $4.10M 10-Q · filed 2025-11-05 | $8.00M derived: sum of 2 quarters · filed 2025-11-05 | $11.30M 10-Q · filed 2025-11-05 | $14.80M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $3.90M 10-Q · filed 2025-08-05 | $7.20M 10-Q · filed 2025-08-05 | $10.70M derived: sum of 3 quarters · filed 2026-02-25 | $14.10M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $3.40M 10-Q · filed 2025-05-05 | $6.80M derived: sum of 2 quarters · filed 2026-02-25 | $10.20M derived: sum of 3 quarters · filed 2026-02-25 | $11.80M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.80M derived: sum of 2 quarters · filed 2026-02-25 | $8.40M derived: sum of 3 quarters · filed 2026-02-25 | $8.50M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $3.40M 10-Q · filed 2024-11-06 | $5.00M derived: sum of 2 quarters · filed 2024-11-06 | $5.10M 10-Q · filed 2024-11-06 | $5.30M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-06-30 | $1.60M 10-Q · filed 2024-08-08 | $1.70M 10-Q · filed 2024-08-08 | $1.90M derived: sum of 3 quarters · filed 2025-02-28 | $1.98M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-03-31 | $152.00K 10-Q · filed 2024-05-09 | $303.00K derived: sum of 2 quarters · filed 2025-02-28 | $379.00K derived: sum of 3 quarters · filed 2025-02-28 | $455.00K derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2022-12-31 | $151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $227.00K derived: sum of 2 quarters · filed 2025-02-28 | $303.00K derived: sum of 3 quarters · filed 2025-02-28 | $379.00K 10-K · filed 2025-02-28 | |||
| 2022-09-30 | $76.00K 10-Q · filed 2023-11-09 | $152.00K derived: sum of 2 quarters · filed 2023-11-09 | $228.00K 10-Q · filed 2023-11-09 | $76.00K 10-Q · filed 2022-11-08 | $304.00K derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | $76.00K 10-Q · filed 2023-08-08 | $152.00K 10-Q · filed 2023-08-08 | $76.00K 10-Q · filed 2022-08-09 | $228.00K derived: sum of 3 quarters · filed 2024-02-29 | $456.00K derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-03-31 | $76.00K 10-Q · filed 2023-05-08 | $152.00K derived: sum of 2 quarters · filed 2024-02-29 | $380.00K derived: sum of 3 quarters · filed 2024-02-29 | $532.00K derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2021-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $304.00K derived: sum of 2 quarters · filed 2024-02-29 | $456.00K derived: sum of 3 quarters · filed 2024-02-29 | $304.00K 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $228.00K 10-Q · filed 2022-11-08 | $76.00K 10-Q · filed 2021-11-10 | $380.00K derived: sum of 2 quarters · filed 2022-11-08 | $228.00K 10-Q · filed 2022-11-08 | $531.00K derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-06-30 | $152.00K 10-Q · filed 2022-08-09 | $76.00K 10-Q · filed 2021-08-13 | $152.00K 10-Q · filed 2022-08-09 | $303.00K derived: sum of 3 quarters · filed 2023-02-27 | $354.00K derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-03-31 | $76.00K 10-Q · filed 2022-05-10 | $151.00K derived: sum of 2 quarters · filed 2023-02-27 | $202.00K derived: sum of 3 quarters · filed 2023-02-27 | $202.00K derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $126.00K derived: sum of 2 quarters · filed 2023-02-27 | $126.00K derived: sum of 3 quarters · filed 2023-02-27 | $126.00K 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $51.00K 10-Q · filed 2021-11-10 | $51.00K derived: sum of 2 quarters · filed 2021-11-10 | $51.00K 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | |||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-12 | ||||||
| 2019-12-31 | $0.00 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |